TOP TALENT FROM DIVERSE BACKGROUNDS

Peter assumed the role of President & Chief Executive Officer in January 2026. He came to Taiho Oncology with more than 30 years of proven experience in oncology commercialization and leadership across pharmaceuticals, medical devices and biotech sectors. Peter joined Taiho Oncology from Alpha Tau Medical, where he was the Chief Commercial Officer and former board member and led the global commercialization efforts for a novel alpha-emitting radiotherapeutic. He was also the CEO of Fortovia Therapeutics and drove the transformation and portfolio expansion in oncology supportive care. In addition, Peter was the Chief Commercial Officer at Novocure.

Michael became Chief Business Officer in 2024. He served as Taiho’s Chief Commercial Officer from 2017 to 2024 and its Vice President of Sales and Marketing from 2013 to 2016. He has been working in oncology since 1996, and began his career in the pharmaceutical and biotech industry at Abbott Pharmaceuticals.

Harold Keer, MD, PhD, joined Taiho Oncology as Chief Medical Officer in January 2024. He has more than 25 years of drug development experience in industry and academia. Most recently, Dr. Keer served as Chief Medical Officer at Astex Pharmaceuticals, Inc., where his numerous accomplishments included leading development activities resulting in the approval of Inqovi® for MDS in the U.S. and Canada, and Inaqovi® for AML in the EU and UK.

Kazu has held a number of leadership roles since joining Taiho Oncology in February 2010, culminating in his current position as Senior Vice President, Finance. During his tenure, he has also overseen Information Technology, Procurement, and Human Resources, playing a pivotal role in transforming Taiho from a clinical development company into a fully integrated commercial organization.

Volker joined Taiho Oncology in May 2020 as Vice President, Clinical Development, and was promoted to Head of Clinical Development in 2023. He oversees the clinical development programs of Taiho Oncology's global oncology portfolio from first-in-human trials through registration studies and lifecycle management, including biomarker development and pharmacokinetic studies.

Sushil has more than 23 years of experience in the pharmaceutical industry. He began his career at Bristol Myers Squibb where he served in various roles, including as leader of the Decision Analysis Group for Oncology. He later joined Daiichi Sankyo, Inc. where he led the Project Management Office and global portfolio management activities before joining Taiho Oncology.

Chris was promoted to Taiho Oncology, Inc.’s Senior Vice President and General Counsel in January 2020. Chris’ work in the legal department has assisted Taiho in transforming the legal function primarily from a development stage contracts department to its present structure of a fully capable legal function within the company.

Kathy joined Taiho Oncology, Inc. as Vice President, Quality in March 2020. Over the past 14 years, Kathy brought her experience to Johnson & Johnson Pharmaceutical, where she served as Head of Compliance, Scientific Systems and Laboratory Operations. Prior to that, she was part of Merck & Company supporting the Vaccine Division in various leadership roles in Laboratory and Quality.

Ed became Vice President, Chief Information Officer in 2020. He started at Taiho Oncology in 2013 as Sr. Director, IT and later became VP, IT in 2016. As the first member of the Taiho Oncology IT organization, he has built a team that provides and supports innovative technology solutions, infrastructure, service desk, validation, cyber security, and data privacy for all regions outside of Asia. His responsibilities also include Facilities.